Axogen, Inc.

LSE:0HKD Stock Report

Market Cap: US$576.5m

Axogen Valuation

Is 0HKD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HKD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0HKD ($12.99) is trading below our estimate of fair value ($38.85)

Significantly Below Fair Value: 0HKD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HKD?

Key metric: As 0HKD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0HKD. This is calculated by dividing 0HKD's market cap by their current revenue.
What is 0HKD's PS Ratio?
PS Ratio3.2x
SalesUS$180.86m
Market CapUS$576.51m

Price to Sales Ratio vs Peers

How does 0HKD's PS Ratio compare to its peers?

The above table shows the PS ratio for 0HKD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.9x
NIOX NIOX Group
6.6x12.1%UK£255.5m
CREO Creo Medical Group
2.2x-4.9%UK£66.9m
EKF EKF Diagnostics Holdings
2.3x7.6%UK£116.6m
AGL ANGLE
16.7x51.5%UK£33.9m
0HKD Axogen
3.2x11.0%US$576.5m

Price-To-Sales vs Peers: 0HKD is good value based on its Price-To-Sales Ratio (3.2x) compared to the peer average (6.9x).

Price to Sales Ratio vs Industry

How does 0HKD's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
SPEC INSPECS Group
0.3x5.5%US$64.26m
YGEN Yourgene Health
0.6xn/aUS$20.48m
IHC Inspiration Healthcare Group
0.4x13.6%US$18.23m
SUN Surgical Innovations Group
0.4xn/aUS$6.42m
No more companies available in this PS range
0HKD 3.2xIndustry Avg. 3.0xNo. of Companies4PS02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0HKD is expensive based on its Price-To-Sales Ratio (3.2x) compared to the UK Medical Equipment industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is 0HKD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HKD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.2x
Fair PS Ratio4x

Price-To-Sales vs Fair Ratio: 0HKD is good value based on its Price-To-Sales Ratio (3.2x) compared to the estimated Fair Price-To-Sales Ratio (4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HKD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$12.99
US$17.83
+37.3%
6.0%US$20.00US$17.00n/a6
Nov ’25US$13.96
US$16.50
+18.2%
15.2%US$20.00US$12.00n/a6
Oct ’25US$14.29
US$15.83
+10.8%
16.1%US$20.00US$12.00n/a6
Sep ’25US$13.07
US$15.83
+21.1%
16.1%US$20.00US$12.00n/a6
Aug ’25US$8.30
US$13.33
+60.7%
18.7%US$17.00US$9.00n/a6
Jul ’25US$7.59
US$13.33
+75.7%
18.7%US$17.00US$9.00n/a6
Jun ’25US$6.81
US$13.40
+96.9%
20.4%US$17.00US$9.00n/a5
May ’25US$6.59
US$13.80
+109.4%
15.5%US$17.00US$11.00n/a5
Apr ’25US$7.92
US$13.80
+74.2%
15.5%US$17.00US$11.00n/a5
Mar ’25US$10.55
US$12.50
+18.5%
24.8%US$17.00US$9.00n/a5
Feb ’25US$9.82
US$12.50
+27.3%
24.8%US$17.00US$9.00n/a5
Jan ’25US$6.85
US$12.40
+81.0%
25.8%US$17.00US$9.00n/a5
Dec ’24US$6.82
US$11.60
+70.1%
25.3%US$17.00US$9.00n/a5
Nov ’24US$3.52
US$14.20
+303.4%
27.2%US$20.00US$9.00US$13.965
Oct ’24US$4.77
US$15.50
+225.3%
20.7%US$20.00US$11.00US$14.294
Sep ’24n/a
US$15.50
0%
20.7%US$20.00US$11.00US$13.074
Aug ’24US$8.55
US$16.25
+90.0%
15.9%US$20.00US$13.00US$8.304
Jul ’24n/a
US$16.25
0%
15.9%US$20.00US$13.00US$7.594
Jun ’24US$8.48
US$16.25
+91.6%
15.9%US$20.00US$13.00US$6.814
May ’24n/a
US$16.25
0%
15.9%US$20.00US$13.00US$6.594
Apr ’24US$9.04
US$16.25
+79.8%
15.9%US$20.00US$13.00US$7.924
Mar ’24n/a
US$16.75
0%
12.2%US$20.00US$15.00US$10.554
Feb ’24US$9.19
US$16.75
+82.2%
12.2%US$20.00US$15.00US$9.824
Jan ’24n/a
US$17.00
0%
12.5%US$20.00US$15.00US$6.854
Dec ’23US$10.15
US$17.75
+74.9%
10.1%US$20.00US$15.00US$6.824
Nov ’23US$11.65
US$20.00
+71.7%
17.7%US$25.00US$15.00US$3.524

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Elevance Health

US$93.6b

Operates as a health benefits company in the United States.

0HG8

US$402.06

7D

0.02%

1Y

-16.0%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.32

7D

4.9%

1Y

-18.6%

Kooth

UK£60.0m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.65

7D

1.5%

1Y

-45.2%